Vagina-Organ-On-A-Chip Model Development Service
Inquiry
Background Vagina-on-a-chip Applications Why Choose Us? FAQs Products
Creative Biolabs' Vagina-On-A-Chip Model Development Service offers a powerful and versatile platform for advancing your research in women's health. We provide tailored solutions to meet your specific project needs, delivering:
Contact our team to get an inquiry now!
Background
The vaginal canal serves as a biomechanical conduit between uterine and external genital structures, maintaining a specialized microbiota where Lactobacillus spp. prevail. These acidogenic species preserve a sub-4.5 pH milieu through lactate synthesis while secreting bacteriostatic agents that antagonize opportunistic pathogens (e.g., Gardnerella, Candida). Compromised homeostasis from microbial imbalance, pH alkalization, or hypoestrogenic epithelial thinning elevates susceptibility to polymicrobial overgrowth syndromes (e.g., BV) and ascending pelvic inflammatory sequelae such as cervicitis/salpingitis. Proactive maintenance requires preserving Lactobacillus dominance through pH-stable hygiene practices and supporting mucosal barrier function via estrogen-modulated glycogen metabolism, which fuels beneficial microbiota while producing antimicrobial peptides.
Vagina-on-a-chip
Fig 1. Vagina-on-a-chip.1,3
The vaginal microfluidic system represents a transformative organomimetic platform with dual diagnostic and therapeutic potential for managing gynecological pathologies. Leveraging microscale fluid dynamics, this technology conducts multiplexed biomolecular assays within picoliter chambers, enabling precise quantification of cervicovaginal biomarkers. Crucially, the MVC demonstrates clinical utility in pathogen detection and therapeutic development for conditions ranging from dysbiotic infections to leukorrhea abnormalities.
Engineered with a compartmentalized architecture, the device co-cultures primary vaginal epithelia in apical microchannels against a stromal fibroblast compartment, separated by a semipermeable interface. This configuration replicates the stratified epithelial-stromal interface of native vaginal mucosa within five days of air-liquid interfacing. The platform's configurable architecture enables the controlled introduction of multispecies bacterial communities, recreating pathogen-colonization patterns characteristic of bacterial vaginosis. This functionality establishes the MVC's translational value in decoding host-pathogen crosstalk and advancing precision therapeutics against pelvic inflammatory sequelae and spontaneous preterm labor mitigation.
-
Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip
An optimal vaginal microbiome features dominant Lactobacillus species, which are critical for gynecological wellness. Microbiome imbalances marked by depleted Lactobacillus populations and proliferation of anaerobic/facultative pathogens—recapitulating BV-associated flora—are linked to detrimental clinical outcomes. Novel microbiota-targeting therapeutics remain limited by the absence of biomimetic in vitro platforms that recapitulate the vagina's epithelial-stromal architecture, obstructing investigations into pathogenetic mechanisms and therapeutic candidate screening while delaying the validation of intervention strategies.
Fig 2. Characterization of a microfluidic human vagina-on-a-chip model.2,3
Researchers have developed a biomimetic microfluidic platform simulating human vaginal tissue architecture, incorporating hormone-sensitive epithelial layers co-cultured with stromal cells under oxygen-restricted conditions. This advanced system facilitates parallel assessment of beneficial L. crispatus versus pathogenic G. vaginalis colonization patterns, measuring consequent tissue-specific immune and metabolic reactions. The technology maintained epithelial layer stability during symbiotic colonization, evidenced by dual lactic acid isomer synthesis (D/L forms), sustained sub-4.5 pH levels, and a 68% reduction in inflammatory markers (IL-6/IL-8). Pathogenic colonization triggered epithelial detachment, pH shifts above 5.5, and 4.1x elevated TNF-α/MCP-1 concentrations. A tri-layered membrane design enabled continuous monitoring of microbial signaling across stromal-epithelial barriers through integrated sensors. This breakthrough bridges translational gaps in vaginal health research by modeling dynamic host-microbe exchanges, proving particularly valuable for testing probiotic formulations and pH-modulating treatments. Rigorous quality assessments demonstrated sustained hormone-responsive epithelial development cycles across four-week culturing, enabling longitudinal studies of persistent infections.
Applications
-
Modeling Vaginal Microbiome-Host Interactions: Studying the complex interplay between the vaginal microbiome and the host immune system in health and disease.
-
Investigating Disease Mechanisms: Elucidating the pathogenesis of vaginal infections, such as bacterial vaginosis, candidiasis, and sexually transmitted infections.
-
Evaluating Preclinical Efficacy and Safety: Assessing the safety and efficacy of novel therapeutic agents, such as probiotics, antimicrobial drugs, and hormone therapies.
-
Personalized Medicine: Developing patient-specific models to study individual variations in vaginal health and response to treatment.
-
Studying the impact of hormones on the vaginal environment: Researching how hormonal fluctuations (e.g., menstrual cycle, menopause) affect the vaginal epithelium and microbiome.
-
Analyzing the effects of external factors: Examining how factors like hygiene products, contraceptives, and sexual activity influence vaginal health.
Experience the Creative Biolabs Advantage - Get a Quote Today
Why Choose Us?
Creative Biolabs is a leading provider of innovative solutions for preclinical research, with a strong commitment to advancing women's health. Our Vagina-On-A-Chip Model Development Service offers several key advantages:
-
Physiological Relevance: Our models accurately replicate the complex microenvironment of the human vaginal mucosa, providing a more predictive platform for preclinical studies compared to traditional 2D cell cultures or animal models.
-
Customization: We tailor each Vagina-On-A-Chip model to your specific research needs, ensuring it meets your exact requirements for cell types, culture conditions, and experimental design.
-
Expertise: Our team comprises experienced scientists with expertise in microfluidics, cell biology, and vaginal microbiome research, ensuring the highest quality of service and support.
-
Reliability: We adhere to rigorous quality control standards to ensure the reproducibility and reliability of our Vagina-On-A-Chip models and experimental data.
-
Accelerated Timelines: Our efficient workflow and streamlined processes help you accelerate your research timelines and achieve your goals faster.
-
Data-Driven Results: We provide comprehensive data analysis and reporting, enabling you to make informed decisions based on robust scientific evidence.
-
Published Data: Our technology is supported by published data demonstrating its effectiveness in modeling vaginal microbiome-host interactions and evaluating potential therapeutics
FAQs
Q: What advantages does the Vagina-on-a-Chip platform offer over conventional cell culture systems?
A: This organomimetic chip system outperforms conventional 2D models by recapitulating vaginal tissue's layered cellular organization, mechanobiological stimuli, and biochemical signaling networks. Its perfusion-driven 3D matrix replicates in vivo-like tissue functionality, enabling complex physiological responses absent in stationary cultures and markedly improving preclinical accuracy for mucosal disease research.
Q: Are bespoke modifications possible for specialized research applications?
A: Customizable configurations allow adaptation of cellular components (primary/epithelial/stromal), microbial integration protocols, and hormonal cycling parameters. Researchers can simulate specific pathophysiological states, from infectious dynamics to hormonal fluctuations, through adjustable flow rates and oxygenation gradients.
Q: How effective is this model for therapeutic development workflows?
A: The system accelerates preclinical pharmacological assessments by enabling real-time analysis of therapeutic candidates' mucosal permeability, microbiome interactions, and epithelial barrier impacts. Its human-relevant fluidic microenvironment reduces reliance on animal models during early-stage efficacy/toxicity screening.
Recommended Products
For researchers facing challenges in initiating microfluidic cellular investigations de novo, Creative Biolabs' engineered cell-culture systems deliver integrated solutions that streamline workflow bottlenecks.
CBLcell™ Organ-on-chip Cell Culture Platform
Creative Biolabs provides you with a full range of microfluidic organ-on-a-chip and cell culture instruments and services to facilitate the start of your research to the greatest extent. If you are overwhelmed by starting a microfluidic cell experiment from scratch, Creative Biolabs' customized platform for cell culture can perfectly solve your problem.
Our chips offer the freedom to choose the cell seeding channels and perfusion conditions, enabling various cell culture modes.
For more information about Creative Biolabs products and services, please contact us.
References
-
Farhang Doost, Negar, and Soumya K. Srivastava. "A comprehensive review of organ-on-a-chip technology and its applications." Biosensors 14.5 (2024): 225.
-
Mahajan, Gautam, et al. "Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip." Microbiome 10.1 (2022): 201.
-
Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not For Clinical Use.
